Abstract
Motivated by the challenge of risk assessment in a heterogeneous population and guided by advances in our knowledge of the pathobiology of cardiovascular diseases (CVD), basic and clinical scientists have maintained substantial interest in the development and application of novel biomarkers for risk stratification of CVD. In particular, strategies to identify and combine multiple biomarkers, which may reflect diverse pathobiological contributors to the onset and complications of CVD, have been arising as an approach to improve more effectively the risk assessment and target therapy. Moreover, comparative evaluations of novel markers are necessary to estimate these candidates for integration into present and future strategies. In this review we consider the recent in-depth knowledge and advances with the use of systemic biomarkers in the area of CVD with special attention on inflammatory markers and those that can predict an individual arteriosclerotic disease stage.
Keywords: Cardiovascular disease, systemic biomarkers, diagnosis, prognosis, atherosclerosis, risk prediction, risk factors, coronary heart disease, inflammation
Current Molecular Medicine
Title: Novel Systemic Cardiovascular Disease Biomarkers
Volume: 10 Issue: 2
Author(s): G. A. Bonaterra, S. Zugel and R. Kinscherf
Affiliation:
Keywords: Cardiovascular disease, systemic biomarkers, diagnosis, prognosis, atherosclerosis, risk prediction, risk factors, coronary heart disease, inflammation
Abstract: Motivated by the challenge of risk assessment in a heterogeneous population and guided by advances in our knowledge of the pathobiology of cardiovascular diseases (CVD), basic and clinical scientists have maintained substantial interest in the development and application of novel biomarkers for risk stratification of CVD. In particular, strategies to identify and combine multiple biomarkers, which may reflect diverse pathobiological contributors to the onset and complications of CVD, have been arising as an approach to improve more effectively the risk assessment and target therapy. Moreover, comparative evaluations of novel markers are necessary to estimate these candidates for integration into present and future strategies. In this review we consider the recent in-depth knowledge and advances with the use of systemic biomarkers in the area of CVD with special attention on inflammatory markers and those that can predict an individual arteriosclerotic disease stage.
Export Options
About this article
Cite this article as:
Bonaterra A. G., Zugel S. and Kinscherf R., Novel Systemic Cardiovascular Disease Biomarkers, Current Molecular Medicine 2010; 10 (2) . https://dx.doi.org/10.2174/156652410790963330
DOI https://dx.doi.org/10.2174/156652410790963330 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antioxidant, Anti-Inflammatory and Anticancer Activities of the Methanolic Extract of Thottea siliquosa: An <i>In Vitro</i> and <i>In Silico</i> Study
Recent Patents on Anti-Cancer Drug Discovery Drug Therapy in Brugada Syndrome
Current Drug Targets - Cardiovascular & Hematological Disorders Ghetto Poverty and Pollution in Egypt: A Deadly Threat for Western Countries Caused by New and Infectious Mutants. A Cultural, Social and Microbiological Synopsis
Inflammation & Allergy - Drug Targets (Discontinued) p53 Peptide Prevents LITAF-Induced TNF-Alpha-Mediated Mouse Lung Lesions and Endotoxic Shock
Current Molecular Medicine Testosterone and Cardioprotection Against Myocardial Ischemia
Cardiovascular & Hematological Disorders-Drug Targets Mineralocorticoid Receptor Blockade in the Protection of Target Organ Damage
Cardiovascular & Hematological Agents in Medicinal Chemistry Therapeutic Options and Emerging Alternatives for Multidrug Resistant Staphylococcal Infections
Current Pharmaceutical Design Pharmacotherapy & Surgical Interventions Available for Obesity Management and Importance of Pancreatic Lipase Inhibitory Phytomolecules as Safer Anti-Obesity Therapeutics
Mini-Reviews in Medicinal Chemistry Role of Innate Immunity in Triggering and Tuning of Autoimmune Diabetes
Current Molecular Medicine Pharmacotherapy of Obesity - Benefit, Bias and Hyperbole
Current Medicinal Chemistry A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
Current Cardiology Reviews Acute Phase Proteins In Acute Coronary Syndrome: An up-to-date
Cardiovascular & Hematological Agents in Medicinal Chemistry Pathophysiology of Diabetic Dyslipidaemia
Current Vascular Pharmacology Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) MicroRNAs: Important Epigenetic Regulators in Osteoarthritis
Current Genomics Polyunsaturated Fatty Acids and Cardiovascular Disease
Current Pharmaceutical Design Network Building of Proteins in a Biochemical Pathway: A Computational Biology Related Model for Target Discovery and Drug-Design
Current Bioinformatics Periostin as a Heterofunctional Regulator of Cardiac Development and Disease
Current Genomics COVID-19: Are Experimental Drugs a Cure or Cause?
Current Drug Safety SHP-2 Regulates Growth Factor Dependent Vascular Signalling and Function
Mini-Reviews in Medicinal Chemistry